Navigation überspringen
Universitätsbibliothek Heidelberg
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Chen, Luxia [VerfasserIn]   i
 Alabdullah, Mohamad [VerfasserIn]   i
 Mahnke, Karsten [VerfasserIn]   i
Titel:Adenosine, bridging chronic inflammation and tumor growth
Verf.angabe:Luxia Chen, Mohamad Alabdullah and Karsten Mahnke
E-Jahr:2023
Jahr:31 October 2023
Umfang:13 S.
Fussnoten:Gesehen am 22.01.2024
Titel Quelle:Enthalten in: Frontiers in immunology
Ort Quelle:Lausanne : Frontiers Media, 2010
Band/Heft Quelle:14(2023), Artikel-ID 1258637, Seite 1-13
ISSN Quelle:1664-3224
Abstract:Adenosine (Ado) is a well-known immunosuppressive agent that may be released or generated extracellularly by cells, via degrading ATP by the sequential actions of the ectonucleotides CD39 and CD73. During inflammation Ado is produced by leukocytes and tissue cells by different means to initiate the healing phase. Ado downregulates the activation and the effector functions of different leukocyte (sub-) populations and stimulates proliferation of fibroblasts for re-establishment of intact tissues. Therefore, the anti-inflammatory actions of Ado are already intrinsically triggered during each episode of inflammation. These tissue-regenerating and inflammation-tempering purposes of Ado can become counterproductive. In chronic inflammation, it is possible that Ado-driven anti-inflammatory actions sustain the inflammation and prevent the final clearance of the tissues from possible pathogens. These chronic infections are characterized by increased tissue damage, remodeling and accumulating DNA damage, and are thus prone for tumor formation. Developing tumors may further enhance immunosuppressive actions by producing Ado by themselves, or by "hijacking" CD39+/CD73+ cells that had already developed during chronic inflammation. This review describes different and mostly convergent mechanisms of how Ado-induced immune suppression, initially induced in inflammation, can lead to tumor formation and outgrowth.
DOI:doi:10.3389/fimmu.2023.1258637
URL:kostenfrei: Volltext: https://doi.org/10.3389/fimmu.2023.1258637
 kostenfrei: Volltext: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1258637/full
 DOI: https://doi.org/10.3389/fimmu.2023.1258637
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:A(2A) RECEPTOR AGONISTS
 A(2B) RECEPTORS
 adenosine
 CD4(+) T-LYMPHOCYTES
 chronic inflammation
 CYTOKINE PRODUCTION
 CYTOTOXIC ACTIVITY
 DNA-DAMAGE
 EXTRACELLULAR ADENOSINE
 hypoxia
 immunosuppression
 NATURAL-KILLER-CELLS
 NF-KAPPA-B
 SYNERGISTIC UP-REGULATION
 tumor
K10plus-PPN:1878597183
Verknüpfungen:→ Zeitschrift
 
 
Lokale URL UB: Zum Volltext

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69163976   QR-Code
zum Seitenanfang